Results 161 to 170 of about 71,664 (187)

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancer Med
O'Shaughnessy J, Glidden A, Locke T, Scales A, Gatewood E, Blanck JP, Castaneda-Gill J, Patel S, Mahnke YD, Wang X, Blas P.   +10 more
europepmc   +1 more source

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis. [PDF]

Thorac Cancer
Lin J, Li Q, Zhang P, Fan Y, Cai R, Luo Y, Lan B, Chen S, Wang J, Mo H, Ma F, Wang J, Xu B.   +12 more
europepmc   +1 more source

Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer. [PDF]

JACC CardioOncol
Moore H, Huppert LA, Moslehi JJ, Yang EH, Hatcher S, Thomas A.   +5 more
europepmc   +1 more source

Neoadjuvant pyrotinib for HER2 (IHC 2+/FISH+)/HR+ breast cancer with early non-response: a case report and literature review. [PDF]

Front Med (Lausanne)
Liu J, Peng X, Huang X, Sun J, Geng D.
europepmc   +1 more source

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers, 2021
Mohammad Hasan Soheilifar, Zhixiang Wang, Hamid Maadi   +2 more
exaly  

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

Annals of Oncology, 2012
Josep Tabernero Caturla, Serena Di Cosimo, María Vidal   +2 more
exaly  

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

Annals of Oncology, 2018
Paolo Pronzato, Michele Aieta, Antonio Russo   +2 more
exaly